Baidu
map

Lancet Diab & Endo:对糖耐量受损者(IGT)进行生活方式干预显示出长期获益

2014-08-04 Li G, Zhang P, Wang J, et al lancet中文网

背景资料 干预糖耐量受损人群的生活方式可降低糖尿病的发病率,但是这种干预对全因死亡率和心血管疾病死亡率的影响尚不清楚。 我们对参加大庆糖尿病预防研究的糖耐量受损的成年患者进行了研究,评估干预其生活方式的长期效应对远期疗效的影响。 该研究是一项聚类随机临床试验,来自中国大庆33家诊所的577例糖耐量受损的成年患者被随机分为 (1:1:1:1) 对照组或生活方式干预组(饮食控制组、运动组、

背景资料

干预糖耐量受损人群的生活方式可降低糖尿病的发病率,但是这种干预对全因死亡率和心血管疾病死亡率的影响尚不清楚。 我们对参加大庆糖尿病预防研究的糖耐量受损的成年患者进行了研究,评估干预其生活方式的长期效应对远期疗效的影响。


该研究是一项聚类随机临床试验,来自中国大庆33家诊所的577例糖耐量受损的成年患者被随机分为 (1:1:1:1) 对照组或生活方式干预组(饮食控制组、运动组、饮食加运动组)。 患者于1986年入组试验,干预持续了6年。 2009年,我们对参与者进行了随访,评估了该意向性治疗人群的心血管疾病死亡率、全因死亡率和糖尿病发病率的主要结局。

研究结果

577名患者中有439人被分配到干预组,138人被分配到对照组(其中一人拒绝基线检查)。 这576名参与者中有542人(94%)具有完整的资料,可进行死亡率分析;其中568人(99%)可提供数据进行分析。 在23年的随访期间,共174例参与者死亡(生活方式干预组121例对比对照组53例)。 生活方式干预组的心血管疾病死亡累计发生率为11.9% (95% CI 8.8-15.0),对照组为19.6% (12.9-26.3)(风险比[HR]0.59,95% CI 0.36-0.96;p=0.033)。 生活方式干预组的全因死亡率为28.1% (95% CI 23.9-32.4),对照组为38.4% (30.3—46.5;HR 0.71,95% CI 0.51—0.99;p=0.049)。 生活方式干预组的糖尿病发病率为72.6% (68.4—76.8),对照组为89.9% (84.9—94.9;HR 0.55,95% CI 0.40—0.76;p=0.001)。结果显示 对糖耐量受损者采取为期6年的饮食和运动计划在20多年后显示出有获益。

解读

对糖耐量受损的中国患者开展了为期6年的生活方式干预计划,这种干预可减少心血管疾病的发病率、降低全因死亡率和糖尿病发病率。研究结果阐明了生活方式干预为糖耐量受损患者带来的远期获益,同时也提供了更多的证据,证明将生活方式干预作为控制糖尿病影响的公共卫生措施是有益的。


原始出处:

Li G1, Zhang P2, Wang J3, An Y4, Gong Q4, Gregg EW5, Yang W6, Zhang B6, Shuai Y6, Hong J6, Engelgau MM7, Li H3, Roglic G8, Hu Y3, Bennett PH9.Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80. doi: 10.1016/S2213-8587(14)70057-9. Epub 2014 Apr 3.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
    2015-04-25 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
    2015-04-11 x35042875

    糖尿病肾病进展风险的关系没有发现。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
    2014-08-08 60.55.9.162

    控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1827855, encodeId=d5ef182e8552b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Apr 25 05:59:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20666, encodeId=970c20666a6, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815154, encodeId=e2a1181515451, content=<a href='/topic/show?id=80009e03900' target=_blank style='color:#2F92EE;'>#长期获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97039, encryptionId=80009e03900, topicName=长期获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Mon Nov 03 10:59:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636921, encodeId=d13416369211c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 27 17:59:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10985, encodeId=ef8910985b3, content=控制糖尿病的五架马车,控制一架,研究中其他四架能保证一致吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.9.162, createdTime=Fri Aug 08 19:33:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500564, encodeId=9d3a1500564fe, content=<a href='/topic/show?id=b2cbe6849b2' target=_blank style='color:#2F92EE;'>#糖耐量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76849, encryptionId=b2cbe6849b2, topicName=糖耐量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e659435909, createdName=fengxx, createdTime=Wed Aug 06 05:59:00 CST 2014, time=2014-08-06, status=1, ipAttribution=)]
    2014-08-06 fengxx

相关资讯

CJASN:慢性肾病患者生活方式干预或可改善心脏舒张功能

8月22日在线发表于《美国肾脏病学会临床杂志(Clinical Journal of the American Society of Nephrology)的一项研究表明,慢性肾病(CKD)患者进行为期12个月的运动训练和生活方式干预与心肺适能、身体成分和心脏舒张功能较好具有相关性。该研究纳入90例3—4期进行运动负荷超声心动图的CKD患者,有83例通过筛查并进行了为期12个月的标准护理或

BMJ:生活方式干预不能改善缺血性心脏病预后

作为全球发病率和死亡率的重要原因之一,缺血性心脏病始终受到研究者的关注。人们已经掌握了缺血性心脏病的主要病因,例如吸烟、缺乏锻炼、不健康饮食等,并且研究显示改变上述危险因素可以影响疾病进程。【原文下载】尽管如此,有关危险因素干预方式的研究尚需完善。因此,T Jørgensen教授研究团队在人群水平上评估了系统筛查缺血性心脏病风险因素的实际作用,具体方式为多次生活方式指导对10年缺血性心脏病进展的影

ADA 2014:DPPOS15年随访结果揭晓

糖尿病预防项目转归研究[TheDiabetesPrevention ProgramOutcomes Study(DPPOS)]源于1996年的糖尿病预防项目(DPP),评估强化生活方式干预和口服降糖药能否预防或延缓糖尿病高危人群疾病进展。6月16日的专场揭晓了DPPOS15年随访结果。 DPP纳入美国27个中心3234例糖尿病前期患者,随机接受安慰剂、二甲双胍(MET,850mg bid)和

Baidu
map
Baidu
map
Baidu
map